使用电子剂量监测测量的依从性与HIV/AIDS及耐多药结核病患者中新发抗逆转录病毒耐药和不良结局相关
在南非KwaZulu-Natal一家公立医院开展的前瞻性队列(PRAXIS研究)纳入198例接受抗逆转录病毒治疗(ART)并启动含贝达喹啉耐多药结核(MDR-TB)治疗的MDR-TB/HIV成人,用电子剂量监测(EDM)累计计算6个月依从性。11%有基线ART耐药突变,7.5%在6个月出现新发ART耐药;ART依从性与ART耐药和死亡独立相关,模型显示依从性与新发耐药呈显著线性关联(P < .001),未发现特定阈值。
要点
- EDM测量的ART依从性与新发ART耐药及死亡独立相关。
- 11%有基线ART耐药突变,7.5%在6个月出现新发ART耐药。
- 依从性与新发耐药呈显著线性关联(P < .001),无特定阈值。
核心结论
- 研究结果强调需要ART耐药检测,尤其在MDR-TB/HIV患者中,而资源有限地区目前未将其作为标准诊疗。
- 尽管随访时间短,ART依从性降低与新发耐药和死亡率增加显著相关。
研究设计与样本
- 前瞻性队列(PRAXIS研究),在南非KwaZulu-Natal一家公立医院纳入198例接受ART并启动含贝达喹啉MDR-TB治疗的MDR-TB/HIV成人。
- 参与者使用独立EDM设备测量对贝达喹啉和ART(奈韦拉平或洛匹那韦/利托那韦)的依从性,依从性按6个月累计计算。
- 随访至MDR-TB治疗完成,中位随访17.2个月(四分位距12.2-19.6)。
- 对HIV RNA ≥1000 copies/mL的样本在基线、2个月和6个月进行HIV基因组测序。
主要发现
- 2016年11月至2018年2月共纳入并随访198例MDR-TB/HIV患者,中位随访17.2个月(四分位距12.2-19.6)。
- 11%有基线ART耐药突变,7.5%在6个月出现新发ART耐药。
- ART依从性与ART耐药和死亡独立相关。
- 模型显示ART依从性与新发耐药呈显著线性关联(P < .001),提示强关联但无特定阈值。
临床怎么用
- 作者认为研究结果强调需要ART耐药检测,尤其在MDR-TB/HIV患者中,而资源有限地区目前未将其作为标准诊疗。
局限性
- 尽管随访时间短,ART依从性降低与新发耐药和死亡率增加显著相关。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Medication adherence is known to challenge treatment of human immunodeficiency virus (HIV)/AIDS and multidrug-resistant tuberculosis (MDR-TB). We hypothesized that adherence using electronic dose monitoring (EDM) would identify an antiretroviral therapy (ART) adherence threshold for emergent ART resistance and predict treatment outcomes in patients with MDR-TB and HIV on ART and bedaquiline-containing TB regimens. METHODS: A prospective cohort of adults with MDR-TB and HIV on ART and initiating MDR-TB treatment with bedaquiline were enrolled at a public hospital in KwaZulu-Natal, South Africa (PRAXIS Study). Participants received separate EDM devices that measure adherence to bedaquiline and ART (nevirapine or lopinavir/ritonavir). Adherence was calculated cumulatively over 6 months. Participants were followed through completion of MDR-TB treatment. HIV genome sequencing was performed at baseline and 2 and 6 months on samples with HIV RNA ≥1000 copies/mL. RESULTS: From November 2016 through February 2018, 198 persons with MDR-TB and HIV were enrolled and followed (median, 17.2 months; interquartile range, 12.2-19.6). Eleven percent had baseline ART resistance mutations, and 7.5% developed emergent ART resistance at 6 months. ART adherence was independently associated with ART resistance and mortality. Modeling identified a significant (P < .001), linear association between ART adherence and emergent resistance, suggesting a strong association without a specific threshold. CONCLUSIONS: Our findings highlight the need for ART resistance testing, especially in patients with MDR-TB and HIV, which is currently not the standard of care in resource-limited settings. Despite short follow-up duration, reduced ART adherence was significantly associated with emergent resistance and increased mortality. CLINICAL TRIALS REGISTRATION: NCT03162107.
引用
- Bateman M, Wolf A, Chimukangara B, et al. Adherence Measured Using Electronic Dose Monitoring is Associated with Emergent Antiretroviral Resistance and Poor Outcomes in People with Human Immunodeficiency Virus/AIDS and Multidrug-Resistant Tuberculosis. Clin Infect Dis. 2022. PMID: 35352097. doi:10.1093/cid/ciac232
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。